CCN2 and pancreatic ductal adenocarcinoma: In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), a cancer type with particularly strong tumor-stroma interaction and stromal infiltration, CCN2 has been identified as a major determinant of tumor growth and metastasis, and as a valid therapeutic target (Dornhofer et al. 2006; Bennewith et al. 2009).